10x Genomics Announces Mega-Scale Single Cell Analysis for One Cent Per Cell at Human Cell Atlas General Meeting
At the Human Cell Atlas General Meeting in Milan, 10x Genomics (Nasdaq: TXG) announced plans to deliver 'single cell for a single cent'. The company aims to launch new products and configurations this quarter, enabling mega-scale single cell analysis at a cost as low as $0.01 per cell. These launches will allow for 2.5 million cells per run and 5 million cells per kit, making them the most cost-effective single cell products for high-throughput applications.
10x Genomics also plans to introduce cost-effective products for smaller-scale experiments, with single cell experiments starting at approximately $560 per sample. The company's strategy includes recent launches like the Chromium GEM-X Technology and Chromium Xo instrument, aimed at reducing customer costs and increasing accessibility to single cell analysis.
Durante il Incontro Generale del Human Cell Atlas a Milano, 10x Genomics (Nasdaq: TXG) ha annunciato piani per offrire 'una cellula per un centesimo'. L'azienda prevede di lanciare nuovi prodotti e configurazioni in questo trimestre, consentendo analisi di singole cellule su grande scala a un costo di soli $0,01 per cellula. Questi lanci permetteranno di analizzare 2,5 milioni di cellule per corsa e 5 milioni di cellule per kit, rendendoli i prodotti per singole cellule più economici per applicazioni ad alta capacità.
10x Genomics prevede inoltre di introdurre prodotti economici per esperimenti su piccola scala, con esperimenti su singole cellule che iniziano a circa $560 per campione. La strategia dell'azienda include lanci recenti come la Tecnologia Chromium GEM-X e lo strumento Chromium Xo, mirati a ridurre i costi per i clienti e ad aumentare l'accessibilità all'analisi delle singole cellule.
En la Reunión General del Atlas de Células Humanas en Milán, 10x Genomics (Nasdaq: TXG) anunció planes para ofrecer 'una célula por un centavo'. La empresa tiene como objetivo lanzar nuevos productos y configuraciones este trimestre, lo que permitirá el análisis de células individuales a gran escala a un costo tan bajo como $0.01 por célula. Estos lanzamientos permitirán 2.5 millones de células por corrida y 5 millones de células por kit, convirtiéndolos en los productos de células individuales más rentables para aplicaciones de alto rendimiento.
10x Genomics también planea introducir productos rentables para experimentos de menor escala, con experimentos de células individuales que comienzan en aproximadamente $560 por muestra. La estrategia de la empresa incluye lanzamientos recientes como la Tecnología Chromium GEM-X y el instrumento Chromium Xo, destinados a reducir los costos para los clientes y aumentar la accesibilidad al análisis de células individuales.
밀라노에서 열린 인간 세포 아틀라스 총회에서, 10x Genomics (Nasdaq: TXG)는 '세포 하나에 한 센트'를 제공할 계획을 발표했습니다. 이 회사는 이 분기에 새로운 제품과 구성을 출시하여 대규모 단일 세포 분석을 세포당 $0.01의 비용으로 가능하게 하고자 합니다. 이러한 출시를 통해 주행당 250만 세포 및 키트당 500만 세포를 분석할 수 있어, 높은 처리량 응용 분야를 위한 가장 비용 효율적인 단일 세포 제품이 될 것입니다.
또한 10x Genomics는 $560 샘플당 약정으로 더 작은 규모의 실험을 위한 비용 효율적인 제품을 도입할 계획입니다. 회사의 전략에는 고객 비용을 줄이고 단일 세포 분석 접근성을 높이기 위해 최근 출시된 Chromium GEM-X 기술과 Chromium Xo 장비가 포함되어 있습니다.
Lors de la Réunion Générale du Human Cell Atlas à Milan, 10x Genomics (Nasdaq: TXG) a annoncé des projets pour offrir 'une cellule pour un cent'. L'entreprise prévoit de lancer de nouveaux produits et configurations ce trimestre, permettant une analyse à grande échelle des cellules individuelles à un coût aussi bas que 0,01 $ par cellule. Ces lancements permettront d'analyser 2,5 millions de cellules par opération et 5 millions de cellules par kit, en les rendant les produits à cellule unique les plus rentables pour des applications à haute capacité.
10x Genomics prévoit également de proposer des produits rentables pour des expériences à plus petite échelle, avec des expériences de cellules uniques commençant à environ 560 $ par échantillon. La stratégie de l'entreprise comprend des lancements récents comme la Technologie Chromium GEM-X et l'instrument Chromium Xo, visant à réduire les coûts pour les clients et à accroître l'accessibilité à l'analyse des cellules uniques.
Auf dem Human Cell Atlas General Meeting in Mailand hat 10x Genomics (Nasdaq: TXG) Pläne angekündigt, 'eine Zelle für einen Cent' anzubieten. Das Unternehmen plant, in diesem Quartal neue Produkte und Konfigurationen einzuführen, die analysen von einzelnen Zellen in Mega-Skalen zu einem Preis von nur $0,01 pro Zelle ermöglichen werden. Diese Produkte ermöglichen 2,5 Millionen Zellen pro Durchlauf und 5 Millionen Zellen pro Kit, was sie zu den kosteneffektivsten Produkten für Einzelzellanwendungen mit hoher Durchsatzleistung macht.
10x Genomics plant auch die Einführung kostengünstiger Produkte für Experimente im kleineren Maßstab, wobei Einzelzell-Experimente bei etwa $560 pro Probe beginnen. Die Strategie des Unternehmens umfasst aktuelle Produkteinführungen wie die Chromium GEM-X Technologie und das Chromium Xo Gerät, die darauf abzielen, die Kosten für Kunden zu senken und den Zugang zur Einzelzellanalyse zu erhöhen.
- Planned launch of mega-scale single cell analysis products at $0.01 per cell
- New products enabling 2.5 million cells per run and 5 million cells per kit
- Introduction of cost-effective solutions for small-scale experiments at $560 per sample
- Launch of Chromium GEM-X Technology, improving sensitivity and reducing cost per cell
- Introduction of Chromium Xo instrument at $25,000 U.S. list price
- None.
Insights
The announcement of 10x Genomics' plan to offer single cell analysis at
The company's strategy to "democratize access" to single cell analysis through various price points is clever. By offering solutions for both mega-scale applications and smaller experiments (at
The introduction of the Chromium Xo instrument at
While these developments are promising, investors should monitor how these price reductions impact margins and overall profitability. The success of this strategy will depend on whether increased volume can offset lower per-unit revenues.
10x Genomics' announcement of mega-scale single cell analysis at
The ability to analyze 2.5 million cells per run and 5 million cells per kit represents a significant increase in throughput. This scalability is important for large-scale projects like the Human Cell Atlas, which aims to map all human cell types.
The company's focus on both high-performance and cost-effectiveness addresses a key pain point in the research community. By removing financial barriers, 10x Genomics could drive widespread adoption of single cell analysis as a standard tool in biological research.
However, competitors may respond with their own price reductions or technological advancements. The long-term success of 10x Genomics will depend on maintaining their technological edge while continuing to improve accessibility and affordability.
During its Foundational Sponsor talk in the Sept. 29 Technology Showcase, 10x Genomics announced an imminent plan to deliver "single cell for a single cent." Through a series of new products and configurations expected to launch this quarter, 10x Genomics intends to deliver mega-scale single cell analysis at a cost as low as
"We know price is an important consideration, both for new researchers embarking on their first single cell experiment and current customers looking to do more – whether that's analyzing more cells or more samples, or running more experiments, more routinely," said Michael Schnall-Levin, Founding Scientist and Chief Technology Officer at 10x Genomics. "By continuing to deliver single cell technologies that offer superior performance and superior economics, we believe we can expand the single cell opportunity, drive widespread adoption and make single cell analysis the standard for most biological research."
In addition to new solutions for mega-scale applications, 10x Genomics' planned launches this quarter will feature cost effective products to increase access to and adoption of single cell in additional applications and use cases. These new offerings are expected to enable researchers to perform single cell experiments, even at a small scale, for approximately
As part of the company's strategy to democratize access to single cell analysis, 10x Genomics introduced several new products earlier this year to drive down customer cost in multiple directions: per cell, per sample, per experiment and per project. This includes:
- Chromium GEM-X Technology: In March, 10x Genomics launched the first two products on its new GEM-X technology architecture, which enables increased sensitivity and capture efficiency, improved robustness and scalability and a more than two-fold reduction in cost per cell.
- Chromium Xo: Last month, 10x Genomics announced the launch of Chromium Xo, the company's most affordable single cell instrument. Chromium Xo delivers the high-quality data, superior reproducibility and ease of use that the company's instrument-powered workflows are known for, at a
U.S. list price of$25,000
"For nearly a decade, researchers have known 10x as the single cell technology leader," added Schnall-Levin. "Our upcoming launches will reinforce Chromium's leadership in both high performance and low cost, because researchers should never have to compromise one for the other. We can't wait to show the world what we've been working on."
About 10x Genomics
10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn or X (Twitter).
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which fall under the "safe harbor" provisions of those sections. All statements, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "might," "will," "should," "expect," "plan," "anticipate," "see," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements regarding 10x Genomics, Inc.'s ("10x Genomics") and others' product launches, performance, configuration, costs, capabilities, requirements, workflows, applications, adoption, opportunities, leadership and pipeline. These statements are based on management's current expectations, forecasts, beliefs, assumptions and information currently available to management, and actual outcomes and results could differ materially from these statements due to a number of factors. Other risks and uncertainties that could affect 10x Genomics' financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents 10x Genomics files with the Securities and Exchange Commission (the "SEC") from time to time. Although 10x Genomics believes that the expectations reflected in the forward-looking statements are reasonable, it cannot provide any assurance that these expectations will prove to be correct nor can it guarantee that the future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or occur. The forward-looking statements in this press release are based on information available to 10x Genomics as of the date hereof, and 10x Genomics disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing 10x Genomics' views as of any date subsequent to the date of this press release.
Disclosure Information
10x Genomics uses filings with the Securities and Exchange Commission, our website (www.10xgenomics.com), press releases, public conference calls, public webcasts and our social media accounts as means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD.
Contacts
Investors: investors@10xgenomics.com
Media: media@10xgenomics.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/10x-genomics-announces-mega-scale-single-cell-analysis-for-one-cent-per-cell-at-human-cell-atlas-general-meeting-302264693.html
SOURCE 10x Genomics, Inc.
FAQ
What is 10x Genomics' new cost per cell for single cell analysis?
How many cells can 10x Genomics' new products analyze per run and per kit?
What is the approximate cost for small-scale single cell experiments with 10x Genomics' new offerings?
What is the U.S. list price of 10x Genomics' new Chromium Xo instrument?
